This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer
by Zacks Equity Research
AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome
by Zacks Equity Research
AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting
Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval
by Zacks Equity Research
Roche's (RHHBY) opthalmology drug, Lucentis 0.3 mg prefilled syringe (PFS) is a new method of administering medicine for all forms of diabetic retinopathy.
GlaxoSmithKline Initiates Phase III Combo Study on Benlysta
by Zacks Equity Research
GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.
Prothena Rallies on Multi-Year Collaboration With Celgene
by Zacks Equity Research
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
Roche Tecentriq Phase III Combo Study Meets Primary Endpoint
by Zacks Equity Research
Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Immune Design Poised on Progress of Pipeline Candidates
by Zacks Equity Research
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Is Roche Holding a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Roche Holding AG (RHHBY) stock is a good choice for value-oriented investors right now from multiple angles.
Top Stock Reports for Apple, Adobe & Canadian National
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Adobe (ADBE) and Canadian National (CNI).
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
by Zacks Equity Research
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
Cancer Space Takes Giant Strides: Are Patients Benefiting?
by Kinjel Shah
The new cancer treatments are probably not doing enough to cure patients or help them live longer or better.
PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.
Can New Approvals Help Mylan Stock Turn Around in 2018?
by Zacks Equity Research
Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.
Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
by Zacks Equity Research
Glaxo (GSK) presents data from OSMO study on a new respiratory medicine, Nucala, and on INSPIRING, a phase IIIb study on investigational HIV candidate dolutegravir at medical conferences.
Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down
by Zacks Equity Research
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View
by Zacks Equity Research
Horizon Pharma (HZNP) Q4 results are driven by growth from the orphan unit and the rheumatology business.
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.